The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | The next five years of multiple myeloma treatment
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses the future developments of multiple myeloma treatments. Recently, there has been a major development in the use of daratumumab. However, other treatments have also had a massive impact such as anti-BCMA antibodies, T-cell engagers, CAR T-cells and antibody conjugates such as belantamab. Over the next five years, there will probably be an increase in BCMA targeted therapy and other novel approaches to treatment. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Advisory boards: GSK, Takeda, celgene/BMS, Amgen, Oncopeptides, Sanofi, Janssen
Speakers bureau: GSK, Takeda, celgene/BMS, Amgen, Janssen
Research: Celgene/BMS, Takeda, Onyx
